Research programme: dyslipidaemia therapies - Ligand Pharmaceuticals/AstraZeneca
Latest Information Update: 16 May 2014
At a glance
- Originator Ligand Pharmaceuticals; Omthera Pharmaceuticals
- Developer AstraZeneca; Ligand Pharmaceuticals
- Class Omega 3 fatty acids
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Dyslipidaemias; Hypertriglyceridaemia
Most Recent Events
- 14 May 2014 Early research in Dyslipidaemias, including hypertriglyceridaemia in USA (unspecified route)